Lab
Kaiser Foundation Health Plan of Washington
Kaiser Foundation Health Plan of Washington was paid $11.76M by Medicaid between Jan 2018 and Dec 2024, across 176 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 18% of everything it billed.
33Billing provider infoKAISER FOUNDATION HEALTH PLAN OF WASHINGTON
RENTON, WA 98057
RENTON, WA 98057
33aNPI1285805119assigned 03/19/2008
33bProvider typeClinical Medical Laboratory
28Total paid$11.76M
24GClaims623,724
24DCodes billed176
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Washington
Rank by total paid#9 of 76
Median peer was paid$90K
This provider vs. median130×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 65,681 | $1.01M | |
| 2019 | 82,809 | $1.41M | |
| 2020 | 80,054 | $1.84M | |
| 2021 | 115,952 | $2.75M | |
| 2022 | 114,480 | $2.23M | |
| 2023 | 116,036 | $1.78M | |
| 2024incomplete | 48,712 | $744K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 18% | 26,381 | 24,276 | $2.16M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 7.0% | 20,146 | 18,819 | $826K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 7.0% | 20,105 | 18,781 | $820K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 6.9% | 7,279 | 7,072 | $813K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.2% | 9,945 | 9,676 | $617K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.7% | 27,134 | 26,625 | $430K |
| 80061 | Lipid panel | 2.6% | 22,359 | 22,044 | $305K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.4% | 11,876 | 11,677 | $287K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.3% | 5,226 | 5,093 | $274K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.3% | 33,479 | 33,084 | $267K |
| 80050 | General health panel | 2.1% | 7,073 | 7,021 | $246K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 31,828 | 30,453 | $245K |
164 more codes
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.8% | 5,972 | $215K |
| 80053 | Comprehensive metabolic panel | 1.8% | 21,231 | $215K |
| 82728 | 1.8% | 15,213 | $207K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.5% | 22,517 | $181K |
| 86003 | 1.3% | 1,563 | $157K | |
| 82607 | 1.3% | 9,810 | $147K | |
| 88142 | 1.2% | 5,730 | $139K | |
| 86803 | 1.1% | 9,017 | $127K | |
| 84403 | 1.1% | 4,866 | $124K | |
| 80081 | <1% | 1,491 | $117K | |
| 82274 | <1% | 6,697 | $112K | |
| 86480 | <1% | 1,775 | $108K | |
| 83550 | <1% | 12,337 | $108K | |
| 87077 | <1% | 11,207 | $98K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,347 | $93K |
| 82565 | <1% | 16,716 | $88K | |
| 83540 | <1% | 12,417 | $80K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12,672 | $78K |
| 83970 | <1% | 1,845 | $74K | |
| 87186 | <1% | 8,080 | $73K | |
| 85027 | <1% | 10,073 | $65K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 774 | $62K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 803 | $51K |
| 87070 | <1% | 5,602 | $49K | |
| 86140 | <1% | 9,274 | $49K | |
| 82043 | <1% | 8,315 | $49K | |
| 82784 | <1% | 3,436 | $46K | |
| 84439 | <1% | 5,094 | $45K | |
| 84460 | <1% | 8,348 | $45K | |
| 82672 | <1% | 2,081 | $44K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 472 | $44K |
| 84702 | <1% | 2,887 | $43K | |
| 84132 | <1% | 8,846 | $43K | |
| 83516 | <1% | 3,335 | $42K | |
| 83001 | <1% | 2,229 | $42K | |
| 87081 | <1% | 6,008 | $40K | |
| 84402 | <1% | 1,513 | $39K | |
| 81001 | <1% | 12,071 | $39K | |
| 84146 | <1% | 1,970 | $39K | |
| 86592 | <1% | 8,562 | $37K | |
| 84450 | <1% | 6,910 | $36K | |
| 82746 | <1% | 2,305 | $34K | |
| 82570 | <1% | 6,496 | $33K | |
| 87210 | <1% | 5,988 | $33K | |
| 87340 | <1% | 3,015 | $31K | |
| 86038 | <1% | 2,533 | $31K | |
| 86235 | <1% | 896 | $30K | |
| 80076 | <1% | 3,650 | $30K | |
| 86706 | <1% | 2,707 | $29K | |
| 85610 | <1% | 6,387 | $27K | |
| 87529 | <1% | 387 | $26K | |
| 87338 | <1% | 1,762 | $25K | |
| 87209 | <1% | 1,363 | $25K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 81 | $24K |
| 86200 | <1% | 1,805 | $24K | |
| 87536 | <1% | 253 | $21K | |
| 84295 | <1% | 4,294 | $21K | |
| 83002 | <1% | 1,101 | $21K | |
| 83880 | <1% | 535 | $20K | |
| 87040 | <1% | 1,364 | $20K | |
| 87427 | <1% | 1,565 | $19K | |
| 83735 | <1% | 2,604 | $17K | |
| 84153 | <1% | 913 | $17K | |
| 87632 | <1% | 85 | $17K | |
| 82105 | <1% | 1,024 | $16K | |
| 87045 | <1% | 1,639 | $16K | |
| 87046 | <1% | 1,607 | $15K | |
| 83993 | <1% | 790 | $15K | |
| 82670 | <1% | 493 | $15K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 736 | $14K |
| 82310 | <1% | 2,571 | $13K | |
| 87177 | <1% | 1,362 | $12K | |
| 87522 | Neg quan hep c or qual rna | <1% | 260 | $12K |
| 86704 | <1% | 980 | $11K | |
| 87493 | <1% | 307 | $11K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 395 | $11K |
| 84550 | <1% | 2,424 | $11K | |
| 86696 | <1% | 523 | $10K | |
| 81003 | <1% | 4,149 | $9K | |
| 85652 | <1% | 3,199 | $9K | |
| 80069 | <1% | 1,014 | $9K | |
| 84156 | <1% | 2,347 | $8K | |
| 82533 | <1% | 523 | $8K | |
| 86431 | <1% | 1,414 | $8K | |
| 84165 | <1% | 713 | $8K | |
| 83520 | <1% | 411 | $8K | |
| 82950 | <1% | 1,470 | $7K | |
| 86695 | <1% | 525 | $7K | |
| 83655 | <1% | 520 | $6K | |
| 82947 | <1% | 1,506 | $6K | |
| 86376 | <1% | 424 | $6K | |
| 82550 | <1% | 898 | $6K | |
| 84480 | <1% | 398 | $6K | |
| 86225 | <1% | 407 | $5K | |
| 86787 | <1% | 432 | $5K | |
| 88342 | <1% | 95 | $5K | |
| 87147 | <1% | 788 | $5K | |
| 88304 | <1% | 166 | $4K | |
| 81507 | <1% | 12 | $4K | |
| 83690 | <1% | 583 | $4K | |
| 82627 | <1% | 229 | $4K | |
| 86160 | <1% | 170 | $4K | |
| 84520 | <1% | 904 | $4K | |
| 86780 | <1% | 261 | $3K | |
| 84100 | <1% | 768 | $3K | |
| 87329 | <1% | 276 | $3K | |
| 82977 | <1% | 545 | $3K | |
| 84630 | <1% | 248 | $3K | |
| 88141 | <1% | 175 | $2K | |
| 82374 | <1% | 440 | $2K | |
| 86361 | <1% | 77 | $2K | |
| 84144 | <1% | 107 | $2K | |
| 85014 | <1% | 864 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 33 | $2K |
| 83921 | <1% | 99 | $2K | |
| 87280 | <1% | 130 | $2K | |
| 86430 | <1% | 278 | $2K | |
| 82951 | <1% | 116 | $2K | |
| 80178 | <1% | 270 | $2K | |
| 87220 | <1% | 385 | $2K | |
| 85018 | <1% | 752 | $2K | |
| 84425 | <1% | 112 | $2K | |
| 84160 | <1% | 291 | $2K | |
| 87088 | <1% | 197 | $2K | |
| 86765 | <1% | 138 | $1K | |
| 87517 | <1% | 27 | $1K | |
| 82040 | <1% | 258 | $1K | |
| 86762 | <1% | 90 | $1K | |
| 82785 | <1% | 95 | $1K | |
| 86593 | <1% | 262 | $1K | |
| 83021 | <1% | 39 | $952.86 | |
| 87279 | <1% | 63 | $947.02 | |
| 85730 | <1% | 178 | $924.20 | |
| 82150 | <1% | 128 | $876.93 | |
| 83615 | <1% | 137 | $856.81 | |
| 87260 | <1% | 58 | $833.02 | |
| 83718 | <1% | 96 | $811.54 | |
| 82247 | <1% | 129 | $641.86 | |
| 84155 | <1% | 179 | $628.43 | |
| 85007 | <1% | 140 | $538.93 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 14 | $537.74 |
| 82465 | <1% | 115 | $533.15 | |
| 83521 | <1% | 17 | $526.86 | |
| 87101 | <1% | 63 | $498.97 | |
| 86735 | <1% | 42 | $489.06 | |
| 81015 | <1% | 162 | $484.53 | |
| 86708 | <1% | 38 | $465.93 | |
| 84075 | <1% | 74 | $382.28 | |
| 83498 | <1% | 12 | $326.28 | |
| 84134 | <1% | 25 | $324.88 | |
| 86800 | <1% | 25 | $320.21 | |
| 80051 | <1% | 39 | $290.34 | |
| 86308 | <1% | 53 | $282.36 | |
| 83883 | <1% | 13 | $274.57 | |
| 86334 | <1% | 12 | $267.05 | |
| 82378 | <1% | 15 | $263.25 | |
| 82172 | <1% | 12 | $230.34 | |
| 82525 | <1% | 17 | $201.02 | |
| 82390 | <1% | 12 | $137.64 | |
| 89055 | <1% | 25 | $132.50 | |
| 82248 | <1% | 25 | $116.92 | |
| 86255 | <1% | 13 | $113.79 | |
| 83721 | <1% | 14 | $98.39 | |
| 85045 | <1% | 12 | $43.76 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBARLOW, MICHELLE (MANAGER)
Parent organizationKAISER FOUNDATION HEALTH PLAN OF WASHINGTON
| Provider | Location | Paid |
|---|---|---|
| Kaiser Foundation Health Plan of Washington | Renton, WA | $7.54M |
| Kaiser Foundation Health Plan of Washington | Renton, WA | $1.30M |
| Kaiser Foundation Health Plan of Washington | Seattle, WA | $484K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.